Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2

Tomokazu Ohishi(Microbial Chemistry Research Foundation), Yukihiko Hara
PLoS ONE
July 13, 2022
Cited by 45


Related Papers